Literature DB >> 22154086

Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging.

Alessio Giubellino1, Girma M Woldemichael, Carole Sourbier, Martin J Lizak, James F Powers, Arthur S Tischler, Karel Pacak.   

Abstract

Pheochromocytoma is the most common tumor of the adrenal medulla in adults. The lack of sensitive animal models of pheochromocytoma has hindered the study of this tumor and in vivo evaluation of antitumor agents. In this study we generated two sensitive luciferase models using bioluminescent pheochromocytoma cells: an experimental metastasis model to monitor tumor spreading and a subcutaneous model to monitor tumor growth and spontaneous metastasis. These models offer a platform for sensitive, non-invasive and real-time monitoring of pheochromocytoma primary growth and metastatic burden to follow the course of tumor progression and for testing relevant antitumor treatments in metastatic pheochromocytoma. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154086      PMCID: PMC3253957          DOI: 10.1016/j.canlet.2011.10.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

Review 1.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

Review 2.  Firefly luciferase: an adenylate-forming enzyme for multicatalytic functions.

Authors:  Satoshi Inouye
Journal:  Cell Mol Life Sci       Date:  2009-10-27       Impact factor: 9.261

3.  Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model.

Authors:  Sharon A Vantyghem; Sylvia M Wilson; Carl O Postenka; Waleed Al-Katib; Alan B Tuck; Ann F Chambers
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

Review 4.  Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Authors:  James E Talmadge; Rakesh K Singh; Isaiah J Fidler; Avraham Raz
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

Review 5.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

Review 6.  Pheochromocytoma: current approaches and future directions.

Authors:  Joel T Adler; Goswin Y Meyer-Rochow; Herbert Chen; Diana E Benn; Bruce G Robinson; Rebecca S Sippel; Stan B Sidhu
Journal:  Oncologist       Date:  2008-07-10

7.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.

Authors:  Laurence Amar; Eric Baudin; Nelly Burnichon; Séverine Peyrard; Stéphane Silvera; Jérôme Bertherat; Xavier Bertagna; Martin Schlumberger; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo; Pierre-François Plouin
Journal:  J Clin Endocrinol Metab       Date:  2007-07-24       Impact factor: 5.958

Review 8.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

9.  Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature.

Authors:  Lucia Martiniova; Edwin W Lai; Abdel G Elkahloun; Mones Abu-Asab; Andrea Wickremasinghe; Daniel C Solis; Shiromi M Perera; Thanh-Truc Huynh; Irina A Lubensky; Arthur S Tischler; Richard Kvetnansky; Salvatore Alesci; John C Morris; Karel Pacak
Journal:  Clin Exp Metastasis       Date:  2009-01-25       Impact factor: 5.150

Review 10.  Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals.

Authors:  Clara P W Klerk; Renée M Overmeer; Tatjana M H Niers; Henri H Versteeg; Dick J Richel; Tessa Buckle; Cornelis J F Van Noorden; Olaf van Tellingen
Journal:  Biotechniques       Date:  2007-07       Impact factor: 1.993

View more
  14 in total

1.  CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model.

Authors:  Urszula M Domanska; Jennifer C Boer; Hetty Timmer-Bosscha; Marcel A T M van Vugt; Hilde D Hoving; Nathalie M Kliphuis; Stefano Rosati; Henk G van der Poel; Igle Jan de Jong; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Clin Exp Metastasis       Date:  2014-08-26       Impact factor: 5.150

2.  Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

Authors:  Svenja Nölting; Alessio Giubellino; Yasin Tayem; Karen Young; Michael Lauseker; Petra Bullova; Jan Schovanek; Miriam Anver; Stephanie Fliedner; Márta Korbonits; Burkhard Göke; George Vlotides; Ashley Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2014-04-24       Impact factor: 4.736

Review 3.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

4.  In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma.

Authors:  Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Marc Cartellieri; Nan Qin; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Jens Pietzsch; Graeme Eisenhofer; Stefan R Bornstein; Christian G Ziegler
Journal:  Endocrinology       Date:  2014-08-19       Impact factor: 4.736

Review 5.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

6.  Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.

Authors:  Allison F O'Neill; Jason L J Dearling; Yuchuan Wang; Tanya Tupper; Yanping Sun; Jon C Aster; Monica L Calicchio; Antonio R Perez-Atayde; Alan B Packard; Andrew L Kung
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

7.  Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells.

Authors:  Jan Schovanek; Petra Bullova; Yasin Tayem; Alessio Giubellino; Robert Wesley; Nikoletta Lendvai; Svenja Nölting; Juraj Kopacek; Zdenek Frysak; Yves Pommier; Shivaani Kummar; Karel Pacak
Journal:  Endocrinology       Date:  2015-08-12       Impact factor: 4.736

8.  Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.

Authors:  C G Ziegler; M Ullrich; A V Schally; R Bergmann; J Pietzsch; L Gebauer; K Gondek; N Qin; K Pacak; M Ehrhart-Bornstein; G Eisenhofer; S R Bornstein
Journal:  Mol Cell Endocrinol       Date:  2012-12-23       Impact factor: 4.102

9.  Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.

Authors:  Alessio Giubellino; Petra Bullova; Svenja Nölting; Hana Turkova; James F Powers; Qingsong Liu; Sylvie Guichard; Arthur S Tischler; Ashley B Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2013-01-10       Impact factor: 4.736

10.  Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

Authors:  Alessio Giubellino; Carole Sourbier; Min-Jung Lee; Brad Scroggins; Petra Bullova; Michael Landau; Weiwen Ying; Len Neckers; Jane B Trepel; Karel Pacak
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.